Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) Director Richard K. Prins sold 4,000 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $55.86, for a total value of $223,440.00. Following the completion of the sale, the director now owns 31,895 shares in the company, valued at $1,781,654.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Amphastar Pharmaceuticals Price Performance
NASDAQ:AMPH traded up $0.74 during trading hours on Monday, reaching $56.59. The stock had a trading volume of 371,180 shares, compared to its average volume of 393,569. Amphastar Pharmaceuticals, Inc. has a 52 week low of $27.58 and a 52 week high of $67.66. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.68 and a current ratio of 2.11. The company has a 50 day moving average price of $47.41 and a two-hundred day moving average price of $50.66. The stock has a market capitalization of $2.76 billion, a PE ratio of 21.82 and a beta of 0.87.
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Piper Sandler increased their target price on Amphastar Pharmaceuticals from $66.00 to $71.00 in a research note on Wednesday, August 9th. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 13th. Jefferies Financial Group initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They set a “buy” rating and a $70.00 target price on the stock. Finally, Bank of America began coverage on shares of Amphastar Pharmaceuticals in a report on Friday. They set a “neutral” rating and a $63.00 price objective for the company.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
A number of large investors have recently made changes to their positions in AMPH. Envestnet Asset Management Inc. purchased a new stake in Amphastar Pharmaceuticals during the first quarter worth $238,000. Raymond James & Associates acquired a new stake in Amphastar Pharmaceuticals during the 1st quarter valued at approximately $599,000. Bank of New York Mellon Corp raised its stake in shares of Amphastar Pharmaceuticals by 8.2% during the 1st quarter. Bank of New York Mellon Corp now owns 401,405 shares of the company’s stock valued at $14,409,000 after buying an additional 30,462 shares during the last quarter. Citigroup Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 27.0% in the 1st quarter. Citigroup Inc. now owns 38,664 shares of the company’s stock valued at $1,388,000 after purchasing an additional 8,224 shares during the period. Finally, Bank of Montreal Can grew its position in shares of Amphastar Pharmaceuticals by 2.9% during the 1st quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock valued at $477,000 after acquiring an additional 371 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
- Five stocks we like better than Amphastar Pharmaceuticals
- How to Evaluate a Stock Before Buying
- The most upgraded stocks in November have two things in common
- Investing in Blue-Chip Stocks
- Monday.com rocked earnings like it’s the weekend
- Learn Technical Analysis Skills to Master the Stock Market
- Plan to own one retailer? Make it this one
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.